Average cost

EQS-News: Strong earnings power allows for active risk management in 2023 – consolidated operating profit expected to rise to between €300 million and €350 million in 2024

Retrieved on: 
Wednesday, March 13, 2024

Consolidated operating profit is projected to rise to between €300 million and €350 million in 2024, even though the Bank anticipates continued above-average risk provisions.

Key Points: 
  • Consolidated operating profit is projected to rise to between €300 million and €350 million in 2024, even though the Bank anticipates continued above-average risk provisions.
  • Aareal Bank Group closed the 2023 financial year with consolidated operating profit of €149 million (2022: €239 million).
  • Thanks to its strong earnings power, the Group nonetheless anticipates consolidated operating profit between €300 million and €350 million.
  • The Bank is expected to achieve operating profit of €250 million to €300 million, despite risk provisions projected to remain at above-average levels.

AGTech Announces Second Interim Results Ended December 31, 2023, Revenue Increases 69% Year-on-Year

Retrieved on: 
Wednesday, March 13, 2024

AGTech Announces Second Interim Results Ended December 31, 2023, Revenue Increases 69% Year-on-Year

Key Points: 
  • AGTech Announces Second Interim Results Ended December 31, 2023, Revenue Increases 69% Year-on-Year
    (Hong Kong, February 23, 2024) – AGTech Holdings Limited (“AGTech” or the “Group”, HKEX stock code: 8279) today announced its second interim results for the twelve months ended December 31, 2023.
  • • EBITDA of the Group for the 12-Month Period was approximately HK$39.5 million (Twelve months ended December 31, 2022: Negative EBITDA of approximately HK$37.7 million).
  • The profit for the 12-Month Period was approximately HK$29 million (12 months ended December 31, 2022: loss of approximately HK$131 million).
  • The change from operating loss to profit was mainly due to: (1) the increase in total revenue; (2) the increase in net finance income.

Sequans Communications Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024

Fourth Quarter 2023 Financial Summary:

Key Points: 
  • Fourth Quarter 2023 Financial Summary:
    Revenue: Revenue was $4.8 million, a decrease of 38.7% compared to the third quarter of 2023 and a decrease of 70.0% compared to the fourth quarter of 2022.
  • Gross margin: Gross margin was 12.2% compared to 85.8% in the third quarter of 2023 and compared to 75.3% in the fourth quarter of 2022, reflecting lower licensing revenues in the fourth quarter of 2023 and a provision for slow-moving inventory of $1.3 million, compared to $75,000 in the third quarter of 2023 and $0.3 million in the fourth quarter of 2022.
  • The fourth quarter of 2023 operating loss reflected $0.8 million in general and administrative expenses from legal fees related to the Renesas tender offer, compared with $2.4 million in the third quarter of 2023 and none in the fourth quarter of 2022.
  • Sequans plans to conduct a teleconference and live webcast to discuss the financial results for the fourth quarter of 2023 today, March 7, 2024 at 8:00 a.m.

Dorel Reports Fourth Quarter and 2023 Year-End Results

Retrieved on: 
Monday, March 11, 2024

Revenue for the fourth quarter was US$138.6 million, down US$12.7 million, or 8.4%, from US$151.3 million last year.

Key Points: 
  • Revenue for the fourth quarter was US$138.6 million, down US$12.7 million, or 8.4%, from US$151.3 million last year.
  • Fourth quarter operating loss was US$12.8 million compared to US$18.3 million last year.
  • It should be noted that the seasonality of our business means that our first quarter, while substantially better than the prior year comparison, will not match 2023’s strong fourth quarter performance,” commented Dorel President & CEO, Martin Schwartz.
  • Dorel Industries Inc. will hold a conference call to discuss these results on Tuesday, March 12, 2024 at 11:00 AM Eastern Time.

VALHI REPORTS FOURTH QUARTER 2023 RESULTS

Retrieved on: 
Thursday, March 7, 2024

Net income attributable to Valhi stockholders increased in the fourth quarter of 2023 as compared to the fourth quarter of 2022 primarily due to higher operating results from all of our segments.

Key Points: 
  • Net income attributable to Valhi stockholders increased in the fourth quarter of 2023 as compared to the fourth quarter of 2022 primarily due to higher operating results from all of our segments.
  • The Chemicals Segment’s TiO2 sales volumes were 29% higher in the fourth quarter of 2023 as compared to the fourth quarter of 2022 and 13% lower in the full year of 2023 as compared to the full year of 2022.
  • Average TiO2 selling prices were 11% lower in the fourth quarter of 2023 as compared to the fourth quarter of 2022 and 4% lower in the full year of 2023 as compared to the full year of 2022.
  • TiO2 production volumes were 15% higher in the fourth quarter of 2023 compared to the fourth quarter of 2022 but 19% lower in the full year of 2023 compared to the full year of 2022.

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024

REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • At the American Association for Cancer Research (AACR) Special Conference on pancreatic cancer, Purple Biotech presented new potential PDAC biomarker data for CM24.
  • In February 2023, Purple Biotech acquired a platform of conditionally activated T cell and NK cell engagers that selectively activate immune response within the tumor microenvironment.
  • As of December 31, 2023, Purple Biotech had cash and cash equivalents and short-term deposits of $15.3 million, compared to $31.7 million on December 31, 2022.

HashiCorp Announces Fourth Quarter and Fiscal Year 2024 Financial Results

Retrieved on: 
Tuesday, March 5, 2024

Fourth quarter revenue totaled $155.8 million, representing an increase of 15% year-over-year; fiscal 2024 revenue totaled $583.1 million, representing an increase of 23% year-over-year

Key Points: 
  • Fourth quarter revenue totaled $155.8 million, representing an increase of 15% year-over-year; fiscal 2024 revenue totaled $583.1 million, representing an increase of 23% year-over-year
    Trailing four quarter average Net Dollar Retention Rate was 115% at the end of the fourth quarter of fiscal 2024 and 131% at the end of fourth quarter of fiscal 2023.
  • SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- HashiCorp, Inc. (NASDAQ: HCP), a leading provider of multi-cloud infrastructure automation software, today announced financial results for its fourth quarter and full fiscal year 2024, ended January 31, 2024.
  • HashiCorp ended the fourth quarter of fiscal 2024 with 4,423 customers, up from 4,354 customers at the end of the previous fiscal quarter and 3,870 customers at the end of the fourth quarter of fiscal 2023.
  • Quarterly subscription revenue from HashiCorp Cloud Platform (HCP) reached $21.3 million in the fourth quarter of fiscal 2024, increased from $19.9 million in the previous fiscal quarter and increased from $14.5 million in the fourth quarter of fiscal 2023.

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, March 5, 2024

BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023.
  • SOPHiA GENETICS will host a conference call and live webcast to discuss the fourth quarter and full year 2023 results, and financial guidance for the full year 2024 on Tuesday, March 5, 2024, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time.
  • Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.
  • These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans.

Stereotaxis Reports 2023 Full Year Financial Results

Retrieved on: 
Monday, March 4, 2024

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • They are transformational as they structurally improve our clinical, commercial, financial, and strategic foundation.”
    “Revenue growth amidst this transition has remained challenging.
  • At December 31, 2023, Stereotaxis had cash and cash equivalents, including restricted cash, of $20.6 million and no debt.
  • To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com .

AvePoint Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 29, 2024

JERSEY CITY, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) --  AvePoint (NASDAQ: AVPT), the most advanced platform to optimize SaaS operations and secure collaboration, today announced financial results for the fourth quarter and full year ended December 31, 2023. 

Key Points: 
  • “Our fourth quarter results were an outstanding close to our strongest year yet as a public company,” said Dr. Tianyi Jiang (TJ), CEO and Co-Founder, AvePoint.
  • Gross Profit: GAAP gross profit was $55.0 million, compared to $44.8 million for the fourth quarter of 2022.
  • Non-GAAP gross profit was $56.1 million, compared to $45.9 million for the fourth quarter of 2022.
  • AvePoint will host a conference call today, February 29, 2024, to review its fourth quarter and full year 2023 financial results and to discuss its financial outlook.